Preferential eradication of acute myelogenous leukemia stem cells by fenretinide

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 14, 2013, Pages 5606-5611

  Zhang, Hui ^a   Mi, Jian Qing ^a   Fang, Hai ^a,b   Wang, Zhao ^a   Wang, Chun ^c   Wu, Lin ^a,c   Zhang, Bin ^a   Minden, Mark ^d   Yang, Wen Tao ^a   Wang, Huan Wei ^a   Li, Jun Min ^a   Xi, Xiao Dong ^a   Chen, Sai Juan ^a   Zhang, Ji ^a,b,e   Chen, Zhu ^a,e   Wang, Kan Kan ^a,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; FENRETINIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLCELLULOSE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA STEM CELL; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL DEATH; COLONY FORMATION; CONTROLLED STUDY; DISEASE CONTROL; ERADICATION THERAPY; GENE; GENE REPRESSION; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STRESS; TUMOR ENGRAFTMENT; WNT SIGNALING PATHWAY; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD34; COLONY-FORMING UNITS ASSAY; COMPUTATIONAL BIOLOGY; FENRETINIDE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, SCID; MICROARRAY ANALYSIS; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84875854934     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1302352110     Document Type: Article

References (44)

1. Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106(4):1154-1163.
2. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ (2005) Opinion: The origin of the cancer stem cell: Current controversies and new insights. Nat Rev Cancer 5(11): 899-904.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105-111.
4. Eppert K, et al. (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17(9):1086-1093.
5. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA (2010) Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 304(24):2706-2715.
6. Pearce DJ, et al. (2006) AML engraftment in the NOD/SCID assay reflects the outcome of AML: Implications for our understanding of the heterogeneity of AML. Blood 107(3):1166-1173.
7. van Rhenen A, et al. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11(18):6520-6527.
8. Guzman ML, et al. (2001) Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98(8):2301-2307.
9. Guzman ML, et al. (2001) Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood 97(7):2177-2179.
10. Jordan CT (2010) Targeting myeloid leukemia stem cells. Sci Transl Med 2(31):31ps21.
11. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355(12): 1253-1261.
12. Wang Y, et al. (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 327(5973):1650-1653.
13. Abdel-Wahab O, Levine RL (2010) Metabolism and the leukemic stem cell. J Exp Med 207(4):677-680.
14. Tothova Z, Gilliland DG (2007) FoxO transcription factors and stem cell homeostasis: Insights from the hematopoietic system. Cell Stem Cell 1(2):140-152.
15. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8(7):579-591.
16. Guzman ML, et al. (2007) Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1, 2, 4-thiadiazolidine, 3, 5 dione (TDZD-8). Blood 110(13):4436-4444.
17. Guzman ML, et al. (2005) The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105(11): 4163-4169.
18. Guzman ML, et al. (2007) An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110(13): 4427-4435.
19. Hassane DC, et al. (2008) Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111(12):5654-5662.
20. Formelli F, Barua AB, Olson JA (1996) Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J 10(9):1014-1024.
21. DiPietrantonio AM, et al. (2000) Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 60(16):4331-4335.
22. Goto H, Takahashi H, Fujii H, Ikuta K, Yokota S (2003) N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Int J Hematol 78(3):219-225.
23. Jiang L, et al. (2011) Preferential involvement of both ROS and ceramide in fenretinide- induced apoptosis of HL60 rather than NB4 and U937 cells. Biochem Biophys Res Commun 405(2):314-318.
24. Oridate N, et al. (1997) Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 89(16): 1191-1198.
25. Wu JM, DiPietrantonio AM, Hsieh TC (2001) Mechanism of fenretinide (4-HPR)- induced cell death. Apoptosis 6(5):377-388.
26. Shimada K, et al. (2002) Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Mol Carcinog 35(3):127-137.
27. Malone W, Perloff M, Crowell J, Sigman C, Higley H (2003) Fenretinide: A prototype cancer prevention drug. Expert Opin Investig Drugs 12(11):1829-1842.
28. Schneider BJ, et al. (2009) Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs 27(6):571-578.
29. Veronesi U, et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17(7):1065-1071.
30. Garaventa A, et al. (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9(6):2032-2039.
31. Villablanca JG, et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: A report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24(21):3423-3430.
32. Puduvalli VK, et al. (2004) Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22(21):4282-4289.
33. Du Y, et al. (2006) Coordination of intrinsic, extrinsic, and endoplasmic reticulummediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood 107(4):1582-1590.
34. Fang H, et al. (2011) A topology-preserving selection and clustering approach to multidimensional biological data. OMICS 15(7-8):483-494.
35. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
36. Wang K, et al. (2009) Converting redox signaling to apoptotic activities by stress-responsive regulators HSF1 and NRF2 in fenretinide treated cancer cells. PLoS One 4(10):e7538.
37. Reya T, et al. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423(6938):409-414.
38. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
39. Valk PJ, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350(16):1617-1628.
40. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4):297-309.
41. Anderson MT, Staal FJ, Gitler C, Herzenberg LA, Herzenberg LA (1994) Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc Natl Acad Sci USA 91(24):11527-11531.
42. Takahashi-Yanaga F, Kahn M (2010) Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res 16(12):3153-3162.
43. Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8(2):97-106.
44. Zhu X, et al. (2012) The significance of low PU.1 expression in patients with acute promyelocytic leukemia. J Hematol Oncol 5:22.